Although NAFLD presence did not alter the response to Wy treatment of all PPARα target genes, the expression profiles of Fgf21, Mogat1 and Hmgcr underscore the dysregulation PPARα signalling pathway in NAFLD. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.